City Therapeutics, Inc. Common Stock Net Assets
City Therapeutics, Inc. Common Stock net assets. Based on the latest financial reports, City Therapeutics, Inc. Common Stock (CTY) has net assets worth $-131.72 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($208.61 Million) and total liabilities ($340.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of City Therapeutics, Inc. Common Stock to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-131.72 Million |
| % of Total Assets | -63.14% |
| Annual Growth Rate | N/A |
| 5-Year Change | -100.91% |
| 10-Year Change | -103.09% |
| Growth Volatility | 3779.5 |
Net Assets of City Therapeutics, Inc. Common Stock (2005–2025)
Net assets of City Therapeutics, Inc. Common Stock from 2005 to 2025. This chart illustrates how City Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of City Therapeutics, Inc. Common Stock to measure how much of total assets are equity-financed.
Annual Net Assets for City Therapeutics, Inc. Common Stock (2005–2025)
The table below shows the annual net assets of City Therapeutics, Inc. Common Stock from 2005 to 2025. For live market cap and overall valuation, see City Therapeutics, Inc. Common Stock market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-84.66 Million | -187.70% |
| 2024-12-31 | $-29.43 Million | -100.29% |
| 2019-12-31 | $10.12 Billion | +2.52% |
| 2018-12-31 | $9.87 Billion | +5.69% |
| 2017-12-31 | $9.34 Billion | +7.42% |
| 2016-12-31 | $8.69 Billion | -2.41% |
| 2015-12-31 | $8.91 Billion | -3.01% |
| 2014-12-31 | $9.18 Billion | +281.83% |
| 2013-12-31 | $2.40 Billion | -12.32% |
| 2012-12-31 | $2.74 Billion | +16.97% |
| 2011-12-31 | $2.35 Billion | +116.40% |
| 2010-12-31 | $-14.30 Billion | -5.42% |
| 2009-12-31 | $-13.56 Billion | +5.50% |
| 2008-12-31 | $-14.35 Billion | -4.59% |
| 2007-12-31 | $-13.72 Billion | -12572.73% |
| 2006-12-31 | $110.00 Million | +100.68% |
| 2005-12-31 | $-16.07 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to City Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8910400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
City Therapeutics, Inc. Common Stock Net Assets Breakdown (December 2025)
City Therapeutics, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $4.45 Million | % |
| Total Equity | $-84.66 Million | 100.00% |
City Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of City Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Daily Journal Corp
NASDAQ:DJCO
|
$911.21 Million |
|
Amerigo Resources Ltd.
TO:ARG
|
$911.28 Million |
|
BrightView Holdings
NYSE:BV
|
$912.11 Million |
|
Foshan Electrical and Lighting Co Ltd
SHE:000541
|
$912.30 Million |
|
Ningbo Sunrise Elc Technology Co Ltd Class A
SHE:002937
|
$910.97 Million |
|
SpartanNash Co
NASDAQ:SPTN
|
$910.90 Million |
|
Hunan New Wellful Co Ltd
SHG:600975
|
$910.67 Million |
|
ATEX Resources Inc.
V:ATX
|
$910.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in City Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -29,425,000 to -84,655,000, a change of -55,230,000.
- Net loss of 58,505,000 reduced equity.
- Other factors increased equity by 3,275,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-58.51 Million | -69.11% |
| Other Changes | $3.27 Million | +3.87% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares City Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $-0.61 | $18.10 | x |
| 2025-12-31 | $-1.75 | $18.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently City Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -431.39%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (55.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 41.82% | 9.72% | 0.00x | -0.36x | $743.40 Million |
| 2006 | 69.54% | 12.19% | 0.66x | 8.58x | $1.03 Billion |
| 2007 | 152.71% | 15.11% | 14.11x | 0.72x | $1.39 Billion |
| 2008 | 182.95% | 13.84% | 33.84x | 0.39x | $1.36 Billion |
| 2009 | 383.65% | 12.30% | 8.35x | 3.73x | $1.17 Billion |
| 2010 | 0.00% | 11.67% | 41.95x | 0.00x | $1.17 Billion |
| 2011 | 5.49% | 8.18% | 0.38x | 1.76x | $-445.70 Million |
| 2012 | 8.51% | 9.60% | 0.53x | 1.68x | $-148.40 Million |
| 2013 | 10.03% | 11.01% | 0.55x | 1.67x | $2.70 Million |
| 2014 | 10.56% | 10.98% | 0.39x | 2.45x | $51.70 Million |
| 2015 | 12.06% | 11.98% | 0.42x | 2.41x | $183.30 Million |
| 2016 | 12.48% | 12.18% | 0.42x | 2.43x | $215.80 Million |
| 2017 | 17.75% | 19.38% | 0.41x | 2.24x | $723.30 Million |
| 2018 | 16.87% | 19.60% | 0.41x | 2.09x | $678.20 Million |
| 2019 | 18.06% | 22.40% | 0.39x | 2.08x | $815.30 Million |
| 2024 | 0.00% | -1002.02% | 0.02x | 0.00x | $-24.89 Million |
| 2025 | 0.00% | -431.39% | 0.09x | 0.00x | $-50.04 Million |
Industry Comparison
This section compares City Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $230,249,706
- Average return on equity (ROE) among peers: -88.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| City Therapeutics, Inc. Common Stock (CTY) | $-131.72 Million | 41.82% | N/A | $911.01 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $28.96 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $3.75 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $138.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $15.46 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $45.35 Million | -59.09% | 0.17x | $810.25 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $24.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $18.59 Million | -164.77% | 1.78x | $7.50 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $627.01 Million | -44.91% | 0.25x | $3.23 Billion |
About City Therapeutics, Inc. Common Stock
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as re… Read more